A heightened iron level in MASLD patients may be associated with dysregulation of iron transport in the organism yielding an enhanced dietary iron absorption in the intestine (via upregulation of divalent metal transporter 1—DMT1) and its excessive uptake by the liver (through the upregulation of transferrin receptor 1—TfR1) [44]. Here, SLC11A2 is linked to metabolic dysfunction-associated steatotic liver disease.